NVS — Novartis Returns To Sales Growth As New Drugs Offset Patent Cliff

Novartis reported a 1% rise in second-quarter net sales to $14.41 billion, beating analyst expectations as new drugs like Kisqali and Pluvicto compensated for patent expirations on former top-sellers. The Swiss drugmaker is navigating a major patent cliff but reaffirmed its full-year forecast for low single-digit sales growth. The company continues to pursue acquisitions, including the recent $12 billion purchase of Avidity Biosciences, to bolster its pipeline.